CA 27.29 and CA 15.3 BREAST CANCER MARKERS PANEL Test
Test Name: CA 27.29 and CA 15.3 BREAST CANCER MARKERS PANEL Test
Components: CA 27.29 and CA 15.3
Test Cost: 1870.0 AED
Sample Condition: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history.
Report Delivery: LPL: Daily USA: Sample by 7th of the month; Report after 2-3 weeks
Method: CMIA, Immunoassay
Test Type: Cancer
Doctor: Oncologist, Gynecologist
Test Department:
Pre Test Information: Provide brief clinical history.
The CA 27.29 and CA 15.3 breast cancer markers panel test is a blood test that measures the levels of two specific proteins, CA 27.29 and CA 15.3, in the blood. These proteins are known to be elevated in some cases of breast cancer.
The test is often used to monitor the progression of breast cancer in patients who have already been diagnosed with the disease. It can help determine if the cancer is responding to treatment or if it has come back after treatment.
Elevated levels of CA 27.29 and CA 15.3 may indicate the presence of breast cancer, but it is important to note that these markers can also be elevated in other conditions, such as benign breast disease or non-breast cancers.
Therefore, the test is not diagnostic for breast cancer and should be used in conjunction with other diagnostic tests, such as imaging studies and biopsies.
The CA 27.29 and CA 15.3 breast cancer markers panel test is typically ordered by a healthcare provider and performed in a laboratory. Results are usually reported as numerical values, and the interpretation of these values may vary depending on the specific laboratory and the patient’s individual circumstances.
It is important to discuss the results of this test with a healthcare provider, who can provide further guidance and interpretation based on the patient’s medical history, symptoms, and other diagnostic tests.
| Test Name | CA 27.29 and CA 15.3 BREAST CANCER MARKERS PANEL Test |
|---|---|
| Components | |
| Price | 1870.0 AED |
| Sample Condition | 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide brief clinical history. |
| Report Delivery | LPL: Daily USA: Sample by 7th of the month; Report after 2??3 weeks |
| Method | CMIA, Immunoassay |
| Test type | Cancer |
| Doctor | Oncologist, Gynecologist |
| Test Department: | |
| Pre Test Information | Provide brief clinical history. |
| Test Details | The CA 27.29 and CA 15.3 breast cancer markers panel test is a blood test that measures the levels of two specific proteins, CA 27.29 and CA 15.3, in the blood. These proteins are known to be elevated in some cases of breast cancer. The test is often used to monitor the progression of breast cancer in patients who have already been diagnosed with the disease. It can help determine if the cancer is responding to treatment or if it has come back after treatment. Elevated levels of CA 27.29 and CA 15.3 may indicate the presence of breast cancer, but it is important to note that these markers can also be elevated in other conditions, such as benign breast disease or non-breast cancers. Therefore, the test is not diagnostic for breast cancer and should be used in conjunction with other diagnostic tests, such as imaging studies and biopsies. The CA 27.29 and CA 15.3 breast cancer markers panel test is typically ordered by a healthcare provider and performed in a laboratory. Results are usually reported as numerical values, and the interpretation of these values may vary depending on the specific laboratory and the patient’s individual circumstances. It is important to discuss the results of this test with a healthcare provider, who can provide further guidance and interpretation based on the patient’s medical history, symptoms, and other diagnostic tests. |
